-
CTN 246: Chloroquine to reduce T cell immune activation in HIV-infected individuals
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
-
CTN 242: Canadian observational cohort (CANOC) collaboration
Please Note: This is an observational study and is designed to examine and link HIV/AIDS information drawn from databases across Canada
-
CTN 238: The MAINTAIN study
A randomized control clinical trial of micronutrient and antioxidant supplementation in persons with untreated HIV infection
-
CTN 216: Argon plasma coagulation for anal dysplasia in MSM
A Phase II, prospective, open-label, pilot study of the tolerability, safety, and efficacy of Argon plasma coagulation for the treatment of anal intraepithelial neoplasia grade 2 or 3 in HIV-positive men having sex with men
-
CTN 214: Effect of a one-year course of HAART in acute/early HIV
A randomized trial of highly active antiretroviral therapy in acute/early HIV infection
-
CTN 198: Supportive therapy for adherence with antiretroviral treatment
STAART The purpose of this study was to determine whether a psycho-educational intervention can help people living with HIV handle the challenges of treatment adherence. The study examined the impact of a particular psycho-educational intervention, titled Supportive Therapy for Adherence to Antiretroviral Treatment (STAART), on readiness for treatment, treatment knowledge, coping with side effects, treatment…
-
CTN 194: Peg-interferon and citalopram in co-infection (PICCO)
Trial of Citalopram for the Prevention of Depression
-
CTN 237: Influenza vaccination strategies using Fluviral in HIV-positive adults
Immunogenicity and efficacy study of Fluviral® influenza vaccine strategies in HIV infected Adults: Trial results
-
CTN 221: NGX-4010 for the treatment of painful HIV-associated neuropathy
A multicenter randomized, double-blind, controlled study of NGX-4010 for the treatment of painful HIV-associated neuropathy: Trial results
-
CTN 203: Phase I/II study of Remune® plus Amplivax™
A Phase I/II safety and immunogencity study of a combination of whole-killed HIV-1 antigen and Amplivax, administered with or without IFA, in HIV-1 infected Participants: Trial results
-
CTN 190: Strategies for management of ART (The SMART Study)
A Comparison of Two Ways to Manage Anti-HIV Treatment
Careers
Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v
Learn More